



IPMK (S-14): sc-104943

BACKGROUND

Inositol polyphosphate multikinase (IPMK) belongs to the inositol phosphokinase (IPK) family and is characterized as having a broad substrate specificity. However, IPMK displays a preference for inositol-1,4,5-trisphosphate (Ins(1,4,5)P₃) and inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P₄). IPMK is ubiquitously expressed with the highest expression in skeletal muscle, liver, placenta, lung, peripheral blood leukocytes, kidney, spleen and colon. IPMK is localized to the nucleus, where it may play a role in the regulation of calcium release from intracellular stores and has been implicated as a drug target for cancer therapies. The gene encoding IPMK maps to human chromosome 10, which contains over 800 genes. Notably, disorders linked to genes on chromosome 10 include Cowden syndrome, Cockayne syndrome and Tetrahydrobiopterin deficiency.

REFERENCES

1. Fryns, J.P., et al. 1991. Apparent late-onset Cockayne syndrome and interstitial deletion of the long arm of chromosome 10 (del(10)(q11.23q21.2)). *Am. J. Med. Genet.* 40: 343-344.
2. Thöny, B., et al. 1994. Chromosomal location of two human genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tetrahydropterin synthase maps to 11q22.3-q23.3, and pterin-4 α -carbinolamine dehydratase maps to 10q22. *Genomics* 19: 365-368.
3. Nalaskowski, M.M., et al. 2002. The human homologue of yeast ArgR111 protein is an inositol phosphate multikinase with predominantly nuclear localization. *Biochem. J.* 366 (Pt 2): 549-556.
4. Nalaskowski, M.M. and Mayr, G.W. 2004. The families of kinases removing the Ca²⁺ releasing second messenger Ins(1,4,5)P₃. *Curr. Mol. Med.* 4: 277-290.
5. Rahgozar, M., et al. 2004. Angiotensin II facilitates autoregulation in the perfused mouse kidney: An optimized *in vitro* model for assessment of renal vascular and tubular function. *Nephrology* 9: 288-296.
6. Chang, S.C. and Majerus, P.W. 2006. Inositol polyphosphate multikinase regulates inositol 1,4,5,6-tetrakisphosphate. *Biochem. Biophys. Res. Commun.* 339: 209-216.
7. Morgan-Lappe, S., et al. 2006. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. *Oncogene* 25: 1340-1348.
8. Teresi, R.E., et al. 2007. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. *Am. J. Hum. Genet.* 81: 756-767.
9. Leyman, A., et al. 2007. The absence of expression of the three isoenzymes of the inositol 1,4,5-trisphosphate 3-kinase does not prevent the formation of inositol pentakisphosphate and hexakisphosphate in mouse embryonic fibroblasts. *Cell. Signal.* 19: 1497-1504.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: IPMK (human) mapping to 10q21.1; *lpmk* (mouse) mapping to 10 B5.2.

SOURCE

IPMK (S-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of IPMK of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-104943 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

IPMK (S-14) is recommended for detection of IPMK of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IPMK siRNA (h): sc-90569, IPMK siRNA (m): sc-146261, IPMK shRNA Plasmid (h): sc-90569-SH, IPMK shRNA Plasmid (m): sc-146261-SH, IPMK shRNA (h) Lentiviral Particles: sc-90569-V and IPMK shRNA (m) Lentiviral Particles: sc-146261-V.

Molecular Weight of IPMK: 47 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.